Key Takeaways
- Base business roars back, Cenexi drags: Consolidated revenue jumped 56% YoY on Cenexi consolidation and 15% base business growth, but Cenexi posted a negative EBITDA of ₹72 crore in Q4, pulling consolidated margin to 24%.
- Base business margin hits 37% in Q4, partly shortage-aided: The 37% EBITDA margin was lifted by US shortages, especially in oncology, a benefit management cannot time and one the company was not competitive enough to capture before.
- Cenexi turnaround delayed by a few quarters, thesis intact: Operational disruptions created a €2 crore order backlog and delayed tech transfers; management still targets high-teen margins in 1 to 2 years.
- First dividend signals confidence: The board recommended a 2,000% dividend (₹20/share) , the first since listing, even as Cenexi losses persist.
- What to watch next quarter: Whether Cenexi’s new high-speed line installation begins on schedule in the September quarter, the pace of backlog normalization, and any sign that US shortage benefits are fading.
Base Business Recovery & US Dynamics
- Growth composition: 15% base business growth was driven by new product launches, relaunches of products lost last year (Athenex and Alvogen exit), and market dominance of leading products.
- Pricing stabilized: US pricing was almost flat year-on-year, roughly 1% negative, a sharp improvement from prior erosion.
- Top products performed: 8 of the top 10 products grew substantially, including Enoxaparin where lost contracts were regained and volumes grew 2x to 3x.
- Shortages provided a lift: The 37% base business EBITDA margin was partly helped by US shortages, particularly in oncology. Management noted the company was not competitive enough to compete in that space before, and timing-wise cannot say how long the benefit will stay.
- Annual growth guide: Management guided 14% to 15% annual growth for the US base business, combining base volumes and new launches.
Srinivas Sadu: "Earlier, we were not competitive enough to compete in that space. But because of the shortages, we did get benefit of certain products for sure. But timing-wise, I can't really say how long this will stay."
Cenexi: The Turnaround Math
- Q4 performance: Revenue declined 18% sequentially due to operational disruptions causing an order backlog, and delay in tech transfer for new business intended to replace phasing-out business. Negative EBITDA of ₹72 crore.
- Gross margin is not the problem: Cenexi’s gross margin was 77% in Q4 and 76% over 11 months, but operational issues dragged overall profitability.
- The capacity constraint: Management stated the issue is not orders, with a €2 crore to €2.5 crore order backlog, but capacity. A new high-speed line is planned for installation starting in the September quarter, with commercial ramp-up taking roughly another quarter.
- Revenue ramp path: From a €40 million base, revenue is expected to move to €43 million and then €45 million. At a €5 crore quarterly run rate, expected in roughly 3 quarters, Cenexi should reach positive EBITDA.
- Cost trajectory: Higher maintenance costs this quarter will come down. As expansion completes and volume grows, fixed costs get better utilized, and costs are expected to be lower than today on both a percentage and absolute basis, though some inflation will counter that.
- August shutdown confirmed: The plant will shut down during summer holidays in August; management is pushing the supplier to deliver the new line before the shutdown to use that time for installation.
Srinivas Sadu: "Today, the issue is not orders. We have EUR2 crore to EUR2.5 crore orders of backlog and the consent is the capacity."
Cenexi: The Turnaround Plan
- Short-term actions: Maximize site utilization through extra shifts to normalize the order backlog, and bring in third-party support to optimize preventive maintenance and changeovers.
- Medium-term actions: Move high-volume products within sites to enhance flexibility, and accelerate tech transfer projects for faster new product launches.
- Long-term vision: Establish Cenexi as one of the most advanced CDMOs offering a wide range of sterile injectables and consistently delivering high margins.
- Business development underway: Actively engaging partners on high-margin, complex projects in biologics, complex generics, and NDAs, leveraging the combined strength of Gland and Cenexi with identified cross-selling opportunities.
- Corporate restructuring: Transitioning toward a leaner centralized corporate structure to streamline decision-making, reduce redundancies, and boost agility.
- Leadership change: Alain Kirchmeyer took over as Cenexi CEO and President in February 2024.
Alain Kirchmeyer: "Clearly, our immediate goal is to bring Cenexi back to profitability and in the medium to long term, deliver high-teen margins."
Complex Injectables & Portfolio Progression
- Eribulin launched: Launched as the first major complex product, with the company as the only approved generic in the market currently. Management declined to comment on competitor entry timelines, saying it is too early to give a number but hoping for good results.
- Complex injectables pipeline: 6 approvals received, 4 launched. The next two years are seen as crucial for realizing meaningful results from the complex product portfolio.
- Acceleration strategy: Exploring potential acquisitions, co-development and in-licensing opportunities to accelerate growth in complex injectables.
- Biologics headwinds: Progress is slower than anticipated. In the last year, focus was diverted to getting the base business back and reducing costs. Additionally, the US funding environment has tightened, with smaller development companies, needed for new biologic assets, seeing funding stop. Current focus is on the technical side and skill development, with no near-term growth expected.
Srinivas Sadu: "And also, the exact situation in the US a lot of funding has stopped. And whenever you have a new asset, especially guys entering the biologic space, you need to work with the smaller development companies where the funding has stopped."
Geographic & Market Updates
| Market | Trend | Commentary |
|---|---|---|
| US (base business) | ▲ Strong recovery | Pricing stabilized (~1% negative YoY); relaunches and new launches drove 15% growth; guided 14–15% annual growth. |
| China | ▼ Below expectations | Only 1 product commercialized with not yet substantial contribution; actively collaborating with Fosun to reassess approach. |
| Rest of World | ▲ Growth expected | Recently established businesses anticipated to deliver significant growth over the next 2 to 3 years. |
| India | ▬ Under evaluation | Currently evaluating strategic options to develop a well-considered future plan. |
Quality & Operational Milestones
- Audit record: Over 40 successful audits completed including regulators and partners; all sites operating smoothly with Establishment Inspection Reports received.
- Capacity expansion: Adding one new high-speed ampoule line at the Fosun plant; evaluating further capacity increases for prefilled syringes.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| US base business growth | 14% to 15% annual growth rate, combination of base and new launches | Annual |
| Cenexi positive EBITDA | At €5 crore quarterly run rate, should reach positive EBITDA | ~3 quarters |
| Cenexi high-teen margins | Mid to long-term goal of high-teen EBITDA margins | 1 to 2 years |
| Cenexi new line installation | Installation to begin; commercial ramp-up roughly a quarter after | September quarter |
| Cenexi cost base | Lower cost base in actual terms as expansion completes and volume grows | A few more quarters |
| Complex injectables | Next two years crucial for realizing meaningful results | 2 years |
| Rest of World markets | Significant growth anticipated in recently established businesses | 2 to 3 years |
Key Metrics
| Metric | Q4 FY24 |
|---|---|
| Revenue from operations | ₹1,537.5 cr, +96% YoY |
| Revenue excluding Cenexi | +50% YoY |
| Gross margin | 61%, up from 54% in Q4 FY23 |
| Base business gross margin | 56%, improved YoY |
| EBITDA | ₹358.7 cr, +113% YoY |
| EBITDA margin | 23%, up from 21% in Q4 FY23 |
| Base business EBITDA margin | 37%, up from 21% in Q4 FY23 |
| Net profit (PAT) | ₹192.4 cr, +145% YoY |
| PAT margin | 13% |
| Consolidated effective tax rate | 35%, due to absence of deferred tax asset at Cenexi for PBT losses |
| R&D expenses | ₹43.6 cr |
| ANDAs filed | 4 |
| ANDA approvals received | 6 |
| Cenexi revenue | ₹363.7 cr, -18% QoQ |
| Cenexi gross contribution | 77% |
| Cenexi EBITDA | Negative ₹72 cr |
| Cenexi order backlog | €2 cr to €2.5 cr |
| Base business US growth guidance | 14% to 15% annual growth rate |
| Eribulin addressable market | $170 mn to $180 mn |
| Cash flow from operations (FY24) | ₹996.8 cr for 12 months ended March 31, 2024 |
| Net working capital | ₹2,407.4 cr as of March 31, 2024, flat YoY |
| Cash conversion cycle (FY24) | 169 days, improved from 256 days in FY23 |
| Capital expenditure (FY24) | ₹397.5 cr, of which ₹236.8 cr spent on India facilities |
| Net cash position | ₹2,175.6 cr as of March 31, 2024 |
| Dividend per share | ₹20, first dividend post listing |